Search

You searched for "transurethral"

214 results found

Demanding cases or nightmares in uro-oncology? Sep/Oct 2022

5 September 2022 | | URO - Urologic Oncology
Treatment of prostate cancer in renal transplant recipients is challenging due to a lack of knowledge of the natural history of cancer in these patients, the anatomical position of the graft in the iliac fossa and its proximity to the...

Prostate cancer series: diagnostics 2

4 March 2025 | | URO - Urologic Oncology, URO - Core Urology, URO - Uroradiology
- Click here for Part 1 - A 68-year-old male was referred to the two-week wait prostatic clinic with a serum prostate specific antigen (PSA) of 17. He had no bothersome lower urinary tract symptoms, relevant past medical history or...

Prostate cancer management 1 – non-metastatic disease

2 May 2025 | | URO - Urologic Oncology, URO - Core Urology, URO - Uroradiology
You are referred a 68-year-old gentleman to the rapid access prostate clinic with a serum prostate specific antigen (PSA) of 12ug/L. He is otherwise fit and well with mild voiding lower urinary tract symptoms (LUTS). He undergoes a multi parametric...

Prostate cancer management 2 – metastatic disease

2 July 2025 | | URO - Urologic Oncology, URO - Core Urology, URO - Uroradiology
A 72-year-old gentleman is referred to you in the two-week wait clinic with a prostate specific antigen (PSA) of 22ug/L. He is otherwise fit and well and does not take any regular medication. His multi-parametric magnetic resonance imaging (mpMRI) shows...

ICS updates in continence care: a personal perspective on the role of basic science in urology

1 March 2017 | | URO - Basic Science Research, URO - Functional / Reconstructive Urology
At a urology research meeting in Sheffield a few years ago, a former post doctorate researcher in urology, Mathieu Boudes, said: “Stop calling it basic research, there is nothing basic about it. It is fundamental research to everything urologists do.”...

Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update

4 May 2020 | | URO - Functional / Reconstructive Urology, URO - Infection, URO - Basic Science Research
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...

Virtual reality: a novel approach to pain management during ESWL

4 March 2025 | | URO - Technology, URO - Endourology & Stones
Extracorporeal shock wave lithotripsy (ESWL) is a well-established treatment for kidney and ureteric stone disease, employing high-energy shock waves to fragment stones into smaller pieces for passage through the urinary tract. This article explores the application of virtual reality (VR)...

The bulbocavernosus reflex

6 January 2023 | | URO - Neurourology
Despite its first discovery predating the early-1940s, clinical application of the bulbocavernosus reflex (BCR) has been limited to date. The BCR traditionally involves contraction of the bulbo- and ischiocavernosus pelvic floor muscles, often referred to as the ‘bulbocavernosus muscle’, in...

Mesh in urological surgery in the UK – background, reviews and current status

1 May 2019 | | URO - Infection, URO - Functional / Reconstructive Urology, URO - Neurourology
All UK urologists, unless they have been on a 10-year silent retreat, are by now aware of the controversy surrounding surgical use of mesh in general and urological / urogynaecological use of mesh for the surgical treatment of stress urinary...

EAU Annual Congress 2024

5 April 2024 -8 April 2024
By Arun Sharma, Urologist, West Herts NHS Teaching, Trust Watford, UK. The 2024 Annual EAU meeting was held at the Expo Porte de Versailles in Paris, the 'city of lights'. The opening ceremony was full of razzmatazz and included breath-taking...

IBSA UK&I launches Perovial®: the first licensed injectable option for men with acute Peyronie’s disease

2 February 2026 | Company Profiles, Recruitment & Personnel
A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition. IBSA UK&I today (Monday 2 February 2026) announces the launch of Perovial®, the first licensed hyaluronic acid injectable indicated for the management of Peyronie’s disease (PD)...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

1 May 2017 | | URO - Urologic Oncology
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...